Position in SVTR
Snapshot 2026-11-03- Startup SignalsTop 25%↓19
- Life SciencesTop 25%↓2
- Drug DiscoveryTop 50%–
About
Polyphron trains frontier AI models to manufacture and simulate donor-diverse human tissue, building a physical, high-throughput verification layer that lets AI models of biology test predictions against living human ground truth for drug development.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Funding history
- 2026-09-17Seed$20M
Investors · Quiet Capital, Gradient Ventures, Haystack, CompoundSource · citybiz.co ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Polyphron
AI-driven human tissue manufacturing and drug validation platform
Seed · 2026-09
—
United States
BusinessLatest roundTotal raisedDate- insitro
ML-driven drug discovery modeling high-throughput cellular data and human clinical/genomic data, with in-house pipeline and pharma partnerships
$400M
$400M - Boltz
Open AI models and agents for molecular modeling and drug discovery
Seed · $28M · 2026-01
$28M - Synfini
AI- and robotic automation-driven platform to accelerate small-molecule drug discovery and chemical synthesis
$53M
$53M
China
BusinessLatest roundTotal raisedDate- PerturbMind AI
AI drug discovery powered by geometric world models (virtual cell model AlphaCell)
Angel · 2026-10
— - Phil Rivers Technology
Computational medicine and life world models using AI and high-performance computing to simulate disease mechanisms and drug efficacy…
Series A2 · 2026-08
— - Anew Labs
AI-driven drug discovery and new drug development platform
Undisclosed · $290M · 2026-09 · Valuation $1.5B
$290MValuation $1.5B
Europe
BusinessLatest roundTotal raisedDate- Undecimal Bio
AI-driven discovery of conjugate molecules for extrahepatic targeted delivery of RNA drugs (DELiveri platform)
Seed · 2026-10
— - Isomorphic Labs
AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds it…
Series B · $2.7B · 2026-05
$2.7B - Cyclana Bio
Tissue-level drug discovery model for treating endometriosis
Pre-Seed · $7M · 2025-10
$7M
Other / unspecified
BusinessLatest roundTotal raisedDate- Congruence
Computation-driven drugs for genetic diseases (including CGX-926)
Undisclosed · $32M · 2025-09
$32M - Elixion Biotech
Elixion Biotech is a precision-medicine drug discovery company whose R&D platform integrates quantum physics, causal biology…
— - Halmos Labs
AI-driven automated R&D systems for biotech and pharma that simulate experimental outcomes before wet-lab work and recommend the experiments that most…
—
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Related coverage
Investors that may fit
Y Combinator
39 Life Sciences deals in the last 24 months · 27 at a nearby stage · 32 in NYC Metro
Request intro →General Catalyst
38 Life Sciences deals in the last 24 months · 17 at a nearby stage · 34 in NYC Metro
Request intro →Andreessen Horowitz
22 Life Sciences deals in the last 24 months · 11 at a nearby stage · 20 in NYC Metro
Request intro →Khosla Ventures
21 Life Sciences deals in the last 24 months · 7 at a nearby stage · 20 in NYC Metro
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 3 at a nearby stage · 15 in NYC Metro
Request intro →Lightspeed
16 Life Sciences deals in the last 24 months · 5 at a nearby stage · 14 in NYC Metro
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.